VXA-G1.1-NN clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses VXA-G1.1-NN is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- VXA-G1.1-NN
- 6
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses VXA-G1.1-NN is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years OldCompletedPhase 1VaxartNCT06944717Written as VXA-G1.1-NN
- A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing InfantsCompletedPhase 1VaxartNCT07254728Written as VXA-G1.1-NN
- Norovirus Challenge StudyCompletedPhase 1/2VaxartNCT05212168Written as VXA-G1.1-NN
- A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult VolunteersCompletedPhase 1VaxartNCT05213728Written as VXA-G1.1-NN
- Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus VaccinesCompletedPhase 1/2VaxartNCT04875676Written as VXA-G1.1-NN
- Safety & Immunogenicity Study of Ad5 Based Oral Norovirus VaccinesCompletedPhase 1VaxartNCT03897309Written as VXA-G1.1-NN